Search Results - "Massuti, B."

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation by PORTA, R, SANCHEZ-TORRES, J. M, CATOT, S, ISLA, D, PRADAS, A, GURPIDE, A, DE CASTRO, J, POLO, E, PUIG, T, TARON, M, COLOMER, R, ROSELL, R, PAZ-ARES, L, MASSUTI, B, REGUART, N, MAYO, C, LIANES, P, QUERALT, C, GUILLEM, V, SALINAS, P

“…Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is poor and more effective treatments are urgently needed. We have…”
Get full text

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial by Fernandez-Martos, C., Garcia-Albeniz, X., Pericay, C., Maurel, J., Aparicio, J., Montagut, C., Safont, M.J., Salud, A., Vera, R., Massuti, B., Escudero, P., Alonso, V., Bosch, C., Martin, M., Minsky, B.D.

“…The primary results of our phase II randomized trial suggested that compared with conventional preoperative chemoradiation (CRT), the addition of chemotherapy…”
Get full text

System analysis and test-bed for an atmosphere-breathing electric propulsion system using an inductive plasma thruster by Romano, F., Massuti-Ballester, B., Binder, T., Herdrich, G., Fasoulas, S., Schönherr, T.

“…Challenging space mission scenarios include those in low altitude orbits, where the atmosphere creates significant drag to the S/C and forces their orbit to an…”
Get full text

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy by Martinez-Balibrea, E, Abad, A, Martínez-Cardús, A, Ginés, A, Valladares, M, Navarro, M, Aranda, E, Marcuello, E, Benavides, M, Massutí, B, Carrato, A, Layos, L, Manzano, J L, Moreno, V

“…Background: The impact of thymidylate synthase (TYMS) and UDP-glucoronosyltransferase 1A (UGT1A) germline polymorphisms on the outcome of colorectal cancer…”
Get full text

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy by Vidal, J., Bellosillo, B., Santos Vivas, C., García-Alfonso, P., Carrato, A., Cano, M.T., García-Carbonero, R., Élez, E., Losa, F., Massutí, B., Valladares-Ayerbes, M., Viéitez, J.M., Manzano, J.L., Azuara, D., Gallego, J., Pairet, S., Capellá, G., Salazar, R., Tabernero, J., Aranda, E., Montagut, C.

“…Extended RAS analysis is mandatory in metastatic colorectal cancer (mCRC) patients. The optimal threshold of RAS mutated subclones to identify patients most…”
Get full text

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study by Van Cutsem, E., Boni, C., Tabernero, J., Massuti, B., Middleton, G., Dane, F., Reichardt, P., Pimentel, F.L., Cohn, A., Follana, P., Clemens, M., Zaniboni, A., Moiseyenko, V., Harrison, M., Richards, D.A., Prenen, H., Pernot, S., Ecstein-Fraisse, E., Hitier, S., Rougier, P.

“…Docetaxel/cisplatin/infusional 5-fluorouracil (5-FU; DCF) is a standard chemotherapy regimen for patients with advanced gastric cancer (GC). This phase II…”
Get full text

First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD) by Sastre, J, Aranda, E, Grávalos, C, Massutí, B, Varella-Garcia, M, Rivera, F, Soler, G, Carrato, A, Manzano, J.L, Díaz-Rubio, E, Hidalgo, M

“…Abstract Purpose To evaluate the efficacy and safety of first-line single-agent cetuximab in fit elderly patients with metastatic colorectal cancer, as well as…”
Get full text

Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases by Benlloch, S., Galbis-Caravajal, J.M., Alenda, C., Peiró, F.M., Sanchez-Ronco, M., Rodríguez-Paniagua, J.M., Baschwitz, B., Rojas, E., Massutí, B.

“…Background: Occult lymph node (LN) metastases are clinically relevant and confer a worse prognosis in non-small-cell lung cancer (NSCLC) patients. Current…”
Get full text

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015 by García-Campelo, R., Bernabé, R., Cobo, M., Corral, J., Coves, J., Dómine, M., Nadal, E., Rodriguez-Abreu, D., Viñolas, N., Massuti, B.

“…Lung cancer is the most common cancer worldwide as well as the leading cause of cancer related deaths as reported by Torre et al (CA Cancer J Clin 65:87–108,…”
Get full text

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours by Sastre, J, Massuti, B, Pulido, G, Guillén-Ponce, C, Benavides, M, Manzano, J.L, Reboredo, M, Rivera, F, Grávalos, C, Safont, M.J, Martínez Villacampa, M, Llovet, P, Dotor, E, Díaz-Rubio, E, Aranda, E

“…Abstract Background Frail elderly patients with metastatic colorectal cancer (mCRC) are not candidates for chemotherapy. Monotherapy with anti-epidermal growth…”
Get full text

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial by Camps, C., Massuti, B., Jiménez, A., Maestu, I., Gómez, R. García, Isla, D., González, J. L., Almenar, D., Blasco, A., Rosell, R., Carrato, A., Viñolas, N., Batista, N., Girón, C. García, Galán, A., López, M., Blanco, R., Provencio, M., Diz, P., Felip, E.

“…Background: Docetaxel is a widely accepted second-line treatment in advanced non-small-cell lung cancer (NSCLC) with a risk of myelotoxicity. This study…”
Get full text

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients by de las Peñas, R., Sanchez-Ronco, M., Alberola, V., Taron, M., Camps, C., Garcia-Carbonero, R., Massuti, B., Queralt, C., Botia, M., Garcia-Gomez, R., Isla, D., Cobo, M., Santarpia, M., Cecere, F., Mendez, P., Sanchez, J.J., Rosell, R.

“…Background: Impaired DNA repair capacity may favorably affect survival in cisplatin/gemcitabine-treated non-small-cell lung cancer (NSCLC) patients. We…”
Get full text

Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02 by Rivera, F., Massutí, B., Salcedo, M., Sastre, J., Martínez Galán, J., Valladares-Ayerbes, M., Serrano, R., de Paredes, Mª. L. García, Manzano, J. L., Galán, M., Alsina, M., Yuste Izquierdo, A. L., López, C., Díaz-Rubio, E., Conde, V., Reboredo, M., Cano, Mª. T., Pachón, V., Aranda, E.

“…Purpose Chemotherapy has improved the overall survival (OS) in patients (pts) with advanced gastric cancer (AGC). Docetaxel (D), oxaliplatin (O) and…”
Get full text

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group by Martin, M., Villar, A., Sole-Calvo, A., Gonzalez, R., Massuti, B., Lizon, J., Camps, C., Carrato, A., Casado, A., Candel, M. T., Albanell, J., Aranda, J., Munarriz, B., Campbell, J., Diaz-Rubio, E.

“…Background: The purpose of this study was to determine the relative efficacy of doxorubicin versus methotrexate in combination with intravenous…”
Get full text

3074 Platinum-pemetrexed palliative chemotherapy in malignant pleural mesothelioma from Spanish BEMME database The Spanish Lung Cancer Group (SLCG) by Remon, J, Reguart, N, Garcia, Y, Nadal, E, Lopez-castro, R, Garcia-campelo, R, Martin-martorell, P, Juan, O, Olmedo, E, Trancho, F, Domine, M, Ponce, S, Cumplido, D, Majem, M, Massuti, B, Porta, R, Rodriguez-abreu, D, Provencio, M

Get full text

2128 Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD) by Abad, A, Massuti, B, Gravalos, C, Escudero, P, Guillen-Ponce, C, Manzano, J.L, Ortiz, M.J, Safont, M.J, Gallego, J, Sastre, J, Pericay, C, Duenas, R, Rivera, F, Losa, F, Valladares-Ayerbes, M, Gonzalez, E, Robles, L, Aranda, E, Carrato, A

Get full text

Pharmacogenomics and gemcitabine by Rosell, R., Cobo, M., Isla, D., Camps, C., Massuti, B.

“…Approximately half of lung cancer patients present with metastases, and a large proportion will develop recurrent disease, with median survival to…”
Get full text

Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy by De Castro, J., González-Larriba, J. L., Vázquez, S., Massutí, B., Sanchez-Torres, J. M., Dómine, M., Garrido, P., Calles, A., Artal, A., Collado, R., García, R., Sereno, M., Majem, M., Macías, J. A., Juan, O., Gómez-Codina, J., Hernández, B., Lázaro, M., Ortega, A. L., Cobo, M., Trigo, J. M., Carcereny, E., Rolfo, C., Macia, S., Muñoz, J., Diz, P., Méndez, M., Rosillo, F., Paz-Ares, L., Cardona, J. V., Isla, D.

“…Background/Aim First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer…”
Get full text

Trichomegaly following treatment with gefitinib (ZD1839) by Pascual, J.C., Bañuls, J., Belinchon, I., Blanes, M., Massuti, B.

Get full text

Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer by Provencio, M., Camps, C., Cobo, M., De las Peñas, R., Massuti, B., Blanco, R., Alberola, V., Jimenez, U., Delgado, J. R., Cardenal, F., Tarón, M., Ramírez, J. L., Sanchez, A., Rosell, R.

“…Purpose New therapeutic approaches are being developed based on findings that several genetic abnormalities underlying non-small-cell lung cancer (NSCLC) can…”
Get full text